State of the art and future challenges of urethra-sparing stereotactic body radiotherapy for prostate cancer: a systematic review of literature - Takeaways - MDSpire

State of the art and future challenges of urethra-sparing stereotactic body radiotherapy for prostate cancer: a systematic review of literature

  • By

  • Jennifer Le Guevelou

  • Davide Giovanni Bosetti

  • Francesco Castronovo

  • Antonio Angrisani

  • Renaud de Crevoisier

  • Thomas Zilli

  • September 5, 2023

  • 0 min

Share

  • 1

    Radiation therapy is a primary treatment for localized prostate cancer, with advancements in techniques reducing toxicity.

  • 2

    Hypofractionation, particularly stereotactic body radiation therapy, is becoming standard for localized prostate cancer treatment.

  • 3

    Urethra-sparing techniques in SBRT aim to minimize genitourinary toxicity by optimizing doses delivered to the urethra.

  • 4

    A systematic review identified 13 studies on urethra-sparing SBRT, focusing on toxicity outcomes and optimization approaches.

  • 5

    Urethra-steering and dose-reduction strategies have shown varying degrees of success in reducing GU toxicity in clinical trials.

Original Source(s)

State of the art and future challenges of urethra-sparing stereotactic body radiotherapy for prostate cancer: a systematic review of literature

  • by Jennifer Le Guevelou, Davide Giovanni Bosetti, Francesco Castronovo, Antonio Angrisani, Renaud de Crevoisier, Thomas Zilli

  • September 5, 2023

Related Content

PSMA-PET/CT-based salvage elective nodal radiotherapy for lymph node recurrence following radical prostatectomy

Evaluation of Radiation Therapy Protocols Before and After Biodegradable Hydrogel (SpaceOAR) Administration to Mitigate Rectal Toxicity in Prostate Cancer Patients Receiving Carbon Ion Radiotherapy

Long-term outcomes of active surveillance for clinically localized prostate cancer in a community-based setting: results from a prospective non-interventional study